KR20130077373A - Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose - Google Patents

Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose Download PDF

Info

Publication number
KR20130077373A
KR20130077373A KR1020110146048A KR20110146048A KR20130077373A KR 20130077373 A KR20130077373 A KR 20130077373A KR 1020110146048 A KR1020110146048 A KR 1020110146048A KR 20110146048 A KR20110146048 A KR 20110146048A KR 20130077373 A KR20130077373 A KR 20130077373A
Authority
KR
South Korea
Prior art keywords
coating
film
tablet
coated
minutes
Prior art date
Application number
KR1020110146048A
Other languages
Korean (ko)
Other versions
KR101806262B1 (en
Inventor
김학형
신종만
이계원
김선이
조한민
이진숙
Original Assignee
(주)한국파비스제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)한국파비스제약 filed Critical (주)한국파비스제약
Priority to KR1020110146048A priority Critical patent/KR101806262B1/en
Publication of KR20130077373A publication Critical patent/KR20130077373A/en
Application granted granted Critical
Publication of KR101806262B1 publication Critical patent/KR101806262B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734Alginic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

PURPOSE: A film-coated tablet including alginic acid and carboxymethylcellulose sodium is provided to prevent the rupture of the film of a tablet from moisture effect occurs by long period storage or during circulation. CONSTITUTION: A film-coated tablet includes alginic acid or pharmaceutically-acceptable salt, and carboxymethylcellulose alkaline salt as active ingredients. Polyvinyl alcohol is used as a coating base. Hydroxypropylmethylcellulose is used as an additional coating base. A coating solvent for coating the film is water, not an organic solvent. The film-coated tablet is secondarily coated with the coating solution including ethyl cellulose as a coating base after coating with the coating solution including polyvinyl alcohol.

Description

수분에 안정한 알긴산 및 카르복시메칠셀룰로오스 소디움 함유 필름코팅정제{Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose}Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose

본 발명은 알긴산 또는 이의 약학적으로 허용 가능한 염 및 카르복시메칠셀룰로오스 알칼리염을 포함하는 필름코팅정제에 관한 것으로서, 보다 구체적으로는 수분 등 저장 안정성이 향상된 필름코팅정제에 관한 것이다.The present invention relates to a film-coated tablet containing alginic acid or a pharmaceutically acceptable salt thereof and an carboxymethyl cellulose alkali salt, and more particularly, to a film-coated tablet having improved storage stability such as moisture.

알긴산 및 카르복시메칠셀룰로오스 소디움 복합제는 음식물 섭취 감소를 통한 체중감량의 보조요법으로 사용되어 오고 있다.Alginic acid and carboxymethylcellulose sodium complex have been used as an adjunct to weight loss through reduced food intake.

그러나, 알긴산/카르복시메칠셀룰로오스 소디움 복합제는 흡습성이 강해 필름코팅 시 수분의 사용을 줄여야 할 뿐만 아니라, 제품의 안정성 및 품질보증을 위해 보관 중 수분의 침투를 가능한 억제하는 수단을 강구해야 하는 어려움 점이 있다.However, alginic acid / carboxymethyl cellulose sodium composites have high hygroscopicity, which not only has to reduce the use of water during film coating, but also has a difficulty in finding a means of inhibiting the penetration of water during storage for product stability and quality assurance. .

보관 중 수분의 침투를 막기 위해 두꺼운 필름코팅을 입힐 수 있으나, 수분의 침투를 막기 위해 사용한 필름코팅이 정제의 붕해를 지연시켜 제품의 효능 및 통상적인 시험법에 문제가 되는 경우가 종종 발생하였다.Thick film coatings may be applied to prevent the ingress of moisture during storage, but film coatings used to prevent the ingress of moisture often delay the disintegration of tablets, which is problematic for product efficacy and conventional test methods.

따라서 본 발명이 이루고자 하는 기술적 과제는 알긴산 또는 이의 약학적으로 허용 가능한 염과 카르복시메칠셀룰로오스 알칼리염(바람직하게는 소디움염)을 함유하는 정제에 있어서 장기간 보관 및 유통중에 수분의 영향을 받아 정제의 피막 파손이 발생하는 것이 개선된 필름코팅정제를 제공하는 것이다.
Therefore, the technical problem to be achieved by the present invention is a tablet coating under the influence of moisture during long-term storage and distribution in tablets containing alginic acid or its pharmaceutically acceptable salts and carboxymethylcellulose alkali salts (preferably sodium salts). The occurrence of breakage is to provide an improved film coated tablet.

상기 기술적 과제를 달성하기 위하여, 본 발명은 유효성분으로 알긴산 또는 이의 약학적으로 허용 가능한 염 및 카르복시메칠셀룰로오스 알칼리염을 함유하는 필름코팅정에 있어서, 코팅기제로 폴리비닐알코올 또는 폴리비닐알코올과 하이드록시프로필메칠셀룰로오스를 사용하는 것을 특징으로 하는 정제를 제공한다.In order to achieve the above technical problem, the present invention is a film-coated tablet containing alginic acid or a pharmaceutically acceptable salt thereof and carboxymethyl cellulose alkali salt as an active ingredient, polyvinyl alcohol or polyvinyl alcohol and hydroxy as a coating base It provides a tablet characterized in that the use of propyl methyl cellulose.

본 발명은 매우 다양한 코팅기제들 중에서 주기제로 폴리비닐알코올 사용하게 되면 알긴산/카르복시메칠셀룰로오스 알칼리염 함유 필름코팅정제의 수분에 대한 안정성이 획기적으로 높아진다는 놀라운 사실에 기초한다.The present invention is based on the surprising fact that the use of polyvinyl alcohol as a periodic agent among a wide variety of coating bases significantly increases the water stability of the alginic acid / carboxymethyl cellulose alkali salt-containing film coating tablets.

바람직하게, 상기 폴리비닐알코올을 주요 코팅기제로 사용하는 필름코팅에 있어 코팅용매로 유기용매가 아닌 물을 사용한다.Preferably, in the film coating using the polyvinyl alcohol as the main coating base, water, not an organic solvent, is used as the coating solvent.

보다 바람직하게, 본 발명에 따른 알긴산/카르복시메칠셀룰로오스 알칼리염 함유 필름코팅정은 폴리비닐알코올을 포함하는 코팅액으로 1차 코팅된 후에, 코팅기제로 에칠셀룰로오스를 포함하는 코팅액으로 2차 코팅된다. 이러한 2차 코팅을 통해 알긴산/카르복시메칠셀룰로오스 알칼리염 필름코팅정제의 수분 안정성을 더욱더 높일 수 있다.More preferably, the alginic acid / carboxymethyl cellulose alkali salt-containing film coating tablet according to the present invention is first coated with a coating liquid containing polyvinyl alcohol, and then secondly coated with an coating liquid containing ethyl cellulose as a coating base. Through this secondary coating it is possible to further increase the water stability of the alginic acid / carboxymethyl cellulose alkali salt film coating tablets.

이러한 에칠셀룰로오스를 포함하는 코팅액은 코팅기제로 에칠셀룰로오스 이외에 하이드록시프로필메칠셀룰로오스를 추가로 포함할 수 있다.The coating liquid containing such ethyl cellulose may further include hydroxypropyl methyl cellulose in addition to the ethyl cellulose as a coating base.

본 발명에 따른 필름코팅정제에 있어, 상기 1차 코팅량은 나정 질량의 3-10 중량%이고, 2차 코팅량은 나정 질량의 3-10 중량%인 것이 본 발명의 목적상 가장 바람직하다. 즉, 이러한 코팅량일 경우 수분에 대한 안정성을 확보하면서도 적절한 붕해 시간을 가질 수 있다.In the film coating tablet according to the present invention, it is most preferable for the purpose of the present invention that the primary coating amount is 3-10% by weight of the uncoated mass, and the secondary coating amount is 3-10% by weight of the uncoated mass. That is, in the case of such a coating amount it may have an appropriate disintegration time while ensuring stability for moisture.

본 발명에 따른 필름코팅에 있어, 필름코팅액은 본 발명의 목적을 저해하지 않는 범위 내에서 상기 언급된 코팅기제들 이외에 폴리에칠렌글리콜, 디에칠프탈레이트, 글리세린, 트리아세틴, 프로필렌글리콜, 아세틸트리에칠시트레이트, 트리에칠시트레이트, 글리세릴트리아세테이트, 디부틸세바케이트 등의 가소제; 탈크, 스테아르산, 이산화규소 등의 활택제; 산화티탄, 알루미늄레이크, 산화철, 천연 안료 등의 착색제; 레시틴, 글리세린, 아세틸화된 모노글리세라이드, 미네랄 오일, 카르나우바 왁스 등의 점착방지제; 히드록시프로필메칠셀룰로오스, 히드록시프로필셀룰로오스, 크산탄 고무, 천연 고무, 카르복시메칠셀룰로오스 등의 현탁화제; 락토스, 전분, 활석, 흄드 실리카 등의 유동보조제 등을 추가로 포함할 수 있다.In the film coating according to the present invention, the film coating liquid, in addition to the above-mentioned coating bases within the scope of not impairing the object of the present invention, polyethylene glycol, diethphthalate, glycerin, triacetin, propylene glycol, acetyl triethyl sheet Plasticizers such as late, triethyl citrate, glyceryl triacetate and dibutyl sebacate; Lubricants such as talc, stearic acid and silicon dioxide; Coloring agents such as titanium oxide, aluminum lake, iron oxide, and natural pigments; Anti-sticking agents such as lecithin, glycerin, acetylated monoglycerides, mineral oils, carnauba wax; Suspending agents such as hydroxypropylmethyl cellulose, hydroxypropyl cellulose, xanthan rubber, natural rubber, and carboxymethyl cellulose; It may further include a flow aid such as lactose, starch, talc, fumed silica and the like.

본 발명에 따른 필름코팅정제는 필름코팅의 피막이 물에서 5분 이내에 파열되어 정제의 붕해를 지연시키는 역할을 하지 않는다.
The film coating tablet according to the present invention does not serve to delay the disintegration of the tablet because the film of the film coating is ruptured within 5 minutes in water.

본 발명은 장기간 보관 및 유통중에 수분의 영향을 받아 정제의 피막 파손이 발생하는 것이 개선된, 알긴산 또는 이의 약학적으로 허용 가능한 염과 카르복시메칠셀룰로오스 알칼리염(바람직하게는 소디움염)을 함유하는 필름코팅정제를 제공한다.
The present invention provides a film containing alginic acid or a pharmaceutically acceptable salt thereof and an carboxymethylcellulose alkali salt (preferably sodium salt), which is improved in the occurrence of breakage of tablets under the influence of moisture during long-term storage and distribution. Provide a coated tablet.

도 1은 실시예 11-1에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
도 2는 실시예 11-2에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
도 3은 실시예 12-1에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
도 4는 실시예 12-2에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
도 5는 실시예 13-1에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
도 6은 실시예 13-2에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
도 7은 실시예 14-1에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
도 8은 실시예 14-2에서 제조한 필름코팅정을 가속조건에서 6개월 보관한 후의 성상을 촬영한 사진이다.
Figure 1 is a photograph of the appearance after storing the film coated tablet prepared in Example 11-1 under accelerated conditions for 6 months.
Figure 2 is a photograph of the appearance after storing the film coated tablet prepared in Example 11-2 under accelerated conditions for 6 months.
Figure 3 is a photograph of the appearance after storing the film coated tablet prepared in Example 12-1 under accelerated conditions for 6 months.
Figure 4 is a photograph of the appearance after storing the film coated tablet prepared in Example 12-2 under accelerated conditions for 6 months.
5 is a photograph of the appearance after storing the film coated tablet prepared in Example 13-1 under accelerated conditions for 6 months.
Figure 6 is a photograph of the appearance after storing the film coated tablet prepared in Example 13-2 under accelerated conditions for 6 months.
Figure 7 is a photograph of the appearance after storing the film coated tablet prepared in Example 14-1 under accelerated conditions for 6 months.
Figure 8 is a photograph of the appearance after storing the film coated tablet prepared in Example 14-2 under accelerated conditions for 6 months.

이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.
Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

알긴산 및 Alginic acid and 카르복시메칠셀룰로오스Carboxymethylcellulose 소디움Sodium 함유  contain 나정의Undefined 제조 Produce

알긴산, 카르복시메칠셀룰로오스 소디움, 미결정셀룰로오스, 크로스포비돈, 전분글리콜산나트륨, 옥수수전분, 시트르산(수화물), 라우릴황산나트륨, 및 침강탄산칼슘을 혼합하고, 포비돈을 정제수에 용해하여 결합액으로 사용하여 통상의 제제학적 기술로 과립을 제조하였다. 제조된 과립물에 활택제인 경질무수규산과 스테아르산마그네슘을 별도 혼합하여 통상의 제조방법으로 하기 표 1의 나정을 제조하였다.Alginic acid, carboxymethyl cellulose sodium, microcrystalline cellulose, crospovidone, sodium starch glycolate, corn starch, citric acid (hydrate), sodium lauryl sulfate, and precipitated calcium carbonate are mixed, and povidone is dissolved in purified water and used as a binder liquid. The granules were prepared by the formulation technique. To prepare the granules in Table 1 to prepare a conventional tableting method by separately mixing the glidant hard anhydrous silicic acid and magnesium stearate.

원료명Raw material name 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 실시예 5Example 5 실시예 6Example 6 실시예 7Example 7 알긴산Alginic acid 35.4%35.4% 36.0%36.0% 37.7%37.7% 35.4%35.4% 35.4%35.4% 35.4%35.4% 35.4%35.4% 카르복시메칠셀룰로오스 소디움Carboxymethylcellulose sodium 17.7%17.7% 18.0%18.0% 18.9%18.9% 17.7%17.7% 17.7%17.7% 17.7%17.7% 17.7%17.7% 미결정셀룰로오스101Microcrystalline cellulose 101 5.3%5.3% ×× ×× 1.8%1.8% 1.8%1.8% ×× ×× 크로스포비돈Crospovidone 7.1%7.1% 7.1%7.1% 전분글리콜산나트륨Starch glycolate sodium ×× ×× ×× 4.4%4.4% ×× 4.4%4.4% 4.4%4.4% 옥수수전분Corn starch ×× ×× ×× ×× 4.4%4.4% ×× ×× 시트르산수화물Citric acid hydrate 8.8%8.8% 9.0%9.0% 9.4%9.4% 8.8%8.8% 8.8%8.8% 5.3%5.3% 3.5%3.5% 경질무수규산Light anhydrous silicic acid 4.4%4.4% 20.0%20.0% 3.8%3.8% 3.5%3.5% 3.5%3.5% 3.5%3.5% 3.5%3.5% 포비돈K30Povidone K30 2.7%2.7% 4.5%4.5% 2.8%2.8% 2.7%2.7% 2.7%2.7% 2.7%2.7% 2.7%2.7% 라우릴황산나트륨Sodium lauryl sulfate 5.3%5.3% 5.4%5.4% 5.7%5.7% 5.3%5.3% 5.3%5.3% 3.5%3.5% 5.3%5.3% 침강탄산칼슘Precipitated calcium carbonate 17.7%17.7% 18.0%18.0% 18.9%18.9% 17.7%17.7% 17.7%17.7% 15.9%15.9% 15.9%15.9% 스테아르산 마그네슘Magnesium stearate 2.7%2.7% 5.4%5.4% 2.8%2.8% 2.7%2.7% 2.7%2.7% 4.4%4.4% 4.4%4.4% 질량비 합계Mass ratio total 100.0%100.0% 100.0%100.0% 100.0%100.0% 100.0%100.0% 100.0%100.0% 100.0%100.0% 100.0%100.0%

알긴산 및 Alginic acid and 카르복시메칠셀룰로오스Carboxymethylcellulose 소디움Sodium 함유  contain 필름코팅정의Definition of film coating 제조 Produce

상기 표 1의 나정에 하기 표 2의 조성으로 코팅기제를 제조하였다.To the uncoated tablet of Table 1 was prepared a coating base in the composition of Table 2.

실시예Example 배합목적Purpose of blending 원료명Raw material name 조성(%)Furtherance(%) 실시예 8Example 8 코팅제Coating agent 히프로멜로오스2910Hypromellose 2910 76.576.5 디아세틸모노글리세라이드Diacetyl monoglycerides 5.95.9 탈크Talc 8.88.8 폴리에칠렌글리콜6000Polyethylene Glycol 6000 8.88.8 질량비 합계Mass ratio total 100.0100.0 코팅용매Coating Solvent 에탄올ethanol qsqs 디클로로메탄Dichloromethane qsqs 실시예 9Example 9 코팅제Coating agent 폴리비닐알코올Polyvinyl alcohol 24.024.0 히프로멜로오스2910Hypromellose 2910 11.011.0 폴리에칠렌글리콜4000Polyethylene Glycol 4000 15.015.0 탈크Talc 8.08.0 산화티탄Titanium oxide 42.042.0 질량비 합계Mass ratio total 100.0100.0 코팅용매Coating Solvent 정제수Purified water qsqs 실시예 10Example 10 코팅제Coating agent 히프로멜로오스2910Hypromellose 2910 58.158.1 에칠셀룰로오스Ethyl Cellulose 8.08.0 디에칠프탈레이트Diethylphthalate 8.98.9 탈크Talc 8.08.0 산화티탄Titanium oxide 17.017.0 질량비 합계Mass ratio total 100.0100.0 코팅용매Coating Solvent 에탄올ethanol qsqs 정제수Purified water qsqs

상기 표 2의 조성 및 중량에 따라 하기 표 3의 필름코팅정을 제조하였다.According to the composition and weight of Table 2 to prepare a film coated tablet of Table 3.

실시예Example 사용된 나정Used uncoated tablet 코팅기제 : 조성Coating base: Composition 실시예 11-1Example 11-1 실시예 1Example 1 실시예 8 : 2%Example 8: 2% 실시예 11-2Example 11-2 실시예 1Example 1 실시예 8 : 5%Example 8: 5% 실시예 12-1Example 12-1 실시예 1Example 1 실시예 8 : 2%
실시예 10 : 4%
Example 8: 2%
Example 10: 4%
실시예 12-2Example 12-2 실시예 1Example 1 실시예 8 : 2%
실시예 10 : 3%
Example 8: 2%
Example 10: 3%
실시예 13-1Example 13-1 실시예 1Example 1 실시예 9 : 2%Example 9: 2% 실시예 13-2Example 13-2 실시예 1Example 1 실시예 9 : 5%Example 9: 5% 실시예 14-1Example 14-1 실시예 1Example 1 실시예 9 : 2%
실시예 10 : 4%
Example 9: 2%
Example 10: 4%
실시예 14-2Example 14-2 실시예 1Example 1 실시예 9 : 2%
실시예 10 : 3%
Example 9: 2%
Example 10: 3%

<실험예 1> 성상 평가Experimental Example 1 Appearance Evaluation

상기 표 3에서 제조된 필름코팅정을 45℃, 상대습도 75%의 가속조건에서 6개월 보관하였으며, 6개월 경과 시 성상의 변화를 하기 표 4 및 도 1-8에 나타내었다. 이때 정제 및 필름의 파손 정도에 따른 정제의 성상 유지 정도에 따라 최저 1점에서 최고 5점까지 부여하여 평가하였다.The film-coated tablets prepared in Table 3 were stored for 6 months under accelerated conditions at 45 ° C. and 75% relative humidity. At this time, according to the degree of maintaining the properties of the tablet according to the degree of breakage of the tablet and the film was evaluated by assigning from the lowest 1 point to the maximum 5 points.

실시예Example 성상 유지 정도에 따른 점수Score according to the degree of retention 실시예 11-1Example 11-1 1One 실시예 11-2Example 11-2 22 실시예 12-1Example 12-1 1One 실시예 12-2Example 12-2 22 실시예 13-1Example 13-1 33 실시예 13-2Example 13-2 44 실시예 14-1Example 14-1 55 실시예 14-2Example 14-2 55

코팅제의 조성 및 코팅률에 따른 성상 변화는 실시예에 따라 다르게 나타났고, 그 중 실시예 13과 14의 성상이 가장 우수하였다. 이는 실시예 9과 10의 조성으로 코팅된 정제임은 알 수 있었다. 상기 표 4의 결과로 코팅제의 조성 중 히프로멜로오스를 단독으로 사용하는 것보다는 폴리비닐알코올과 히프로멜로오스와 에칠셀룰로오스의 혼합물을 사용하는 것이 제제의 안정성에 더 효과적인 것을 알 수 있었다. 또한 폴리비닐알코올과 히프로멜로오스와 에칠셀룰로오스의 혼합물로 이루어진 코팅제를 일정한 비율로 사용하는 것이 단독으로 사용하는 것보다 제제의 품질의 안정성에 더 효과적임을 알 수 있었다.
The change in appearance according to the composition and coating rate of the coating agent was different according to the embodiment, and the properties of Examples 13 and 14 were the best. This was found to be a tablet coated with the composition of Examples 9 and 10. As a result of Table 4, it was found that the use of a mixture of polyvinyl alcohol, hypromellose, and ethyl cellulose was more effective in the stability of the formulation than the use of hypromellose alone in the coating composition. In addition, it was found that the use of a coating agent composed of a mixture of polyvinyl alcohol, hypromellose, and ethyl cellulose in a constant ratio was more effective for stability of the quality of the formulation than the use alone.

<실험예 2> 피막파열시간 및 붕해 평가Experimental Example 2 Evaluation of Film Break Time and Disintegration

대한약전 붕해시험법에 따라 상기 실시예 11-14로 제조된 정제의 피막 파열시간 및 붕해 정도를 평가하였다. 붕해 평가 매질은 정제수이었다. 그 결과를 하기 표 5에 나타내었다.The film rupture time and degree of disintegration of the tablets prepared in Example 11-14 were evaluated according to the pharmacopeia dissolution test method. The disintegration evaluation medium was purified water. The results are shown in Table 5 below.

실시예Example 초기Early 6개월 경과6 months 피막 파열Rupture of the film 붕해Disintegration 피막 파열Rupture of the film 붕해Disintegration 실시예 11-1Example 11-1 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 5분 이내Within 5 minutes 실시예 11-2Example 11-2 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 5분 이내Within 5 minutes 실시예 12-1Example 12-1 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 5분 이내Within 5 minutes 실시예 12-2Example 12-2 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 5분 이내Within 5 minutes 실시예 13-1Example 13-1 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 45분 이내Within 45 minutes 실시예 13-2Example 13-2 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 45분 이내Within 45 minutes 실시예 14-1Example 14-1 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 45분 이내Within 45 minutes 실시예 14-2Example 14-2 5분 이내Within 5 minutes 38분 이내Within 38 minutes 5분 이내Within 5 minutes 45분 이내Within 45 minutes

상기 표 5의 결과로 피막 파열시간은 초기 결과와 차이가 없었다. 반면에 실험 초기에는 45분 이내로 붕해시간을 보였던 정제들이 6개월이 경과한 후 코팅제의 조성에 따라 각기 다른 붕해시간을 나타내는 것을 알 수 있었다. 이는 상기 표 4에서도 나타났던 성상과도 연관이 있는 것으로 보여진다. 또한 그 성상 변화가 클 수로 붕해시간은 더 빨라지는 것으로 나타났다. 이는 코팅제가 수분을 차단하지 못해 나정의 결합력을 약하게 해 정제의 경도가 낮아졌고, 이로 인해 붕해 시간이 빨라지는 결과를 나타내는 것으로 추측된다.As a result of Table 5, the film rupture time did not differ from the initial result. On the other hand, tablets that showed disintegration time within 45 minutes at the beginning of the experiment showed different disintegration times depending on the composition of the coating after 6 months. This seems to be related to the appearance shown in Table 4 above. The disintegration time was also faster due to the larger change in appearance. It is believed that the coating did not block the water, weakening the uncoated bond strength, which lowered the hardness of the tablet, resulting in faster disintegration time.

Claims (8)

유효성분으로 알긴산 또는 이의 약학적으로 허용 가능한 염 및 카르복시메칠셀룰로오스 알칼리염을 함유하는 필름코팅정에 있어서,
코팅기제로 폴리비닐알코올을 사용하는 것을 특징으로 하는 정제.
In the film-coated tablet containing alginic acid or a pharmaceutically acceptable salt thereof and carboxymethyl cellulose alkali salt as an active ingredient,
Tablets, characterized in that the use of polyvinyl alcohol as a coating base.
제 1항에 있어서, 상기 필름코팅정은 코팅기제로 하이드록시프로필메칠셀룰로오스를 추가로 사용하는 것을 특징으로 하는 정제.The tablet of claim 1, wherein the film-coated tablet further uses hydroxypropylmethylcellulose as a coating base. 제 1항 또는 제 2항에 있어서, 상기 필름코팅을 함에 있어서 코팅용매로 유기용매가 아닌 물을 사용하는 것을 특징으로 하는 정제.The tablet according to claim 1 or 2, wherein in the film coating, water, not an organic solvent, is used as a coating solvent. 제 1항 또는 제 2항에 있어서, 상기 필름코팅정은 폴리비닐알코올을 포함하는 코팅액으로 1차 코팅된 후에, 코팅기제로 에칠셀룰로오스를 포함하는 코팅액으로 2차 코팅되는 것을 특징으로 하는 정제.The tablet according to claim 1 or 2, wherein the film-coated tablet is first coated with a coating solution containing polyvinyl alcohol and then secondly coated with a coating solution containing ethylcellulose as a coating base. 제 5항에 있어서, 상기 에칠셀룰로오스를 포함하는 코팅액은 코팅기제로 하이드록시프로필메칠셀룰로오스를 추가로 포함하고 있는 것을 특징으로 하는 정제.6. The tablet according to claim 5, wherein the coating liquid containing ethyl cellulose further comprises hydroxypropyl methyl cellulose as a coating base. 제 5항에 있어서, 상기 1차 코팅량은 나정 질량의 3-10 중량%이고, 2차 코팅량은 나정 질량의 3-10 중량%인 것을 특징으로 하는 정제.The tablet according to claim 5, wherein the primary coating amount is 3-10% by weight of the uncoated mass, and the secondary coating amount is 3-10% by weight of the uncoated mass. 제 1항 또는 제 2항에 있어서, 필름코팅의 피막이 물에서 5분 이내에 파열되는 것을 특징으로 하는 정제.The tablet according to claim 1 or 2, wherein the film of the film coating ruptures in water within 5 minutes. 제 5항에 있어서, 필름코팅의 피막이 물에서 5분 이내에 파열되는 것을 특징으로 하는 정제.The tablet according to claim 5, wherein the film-coated film ruptures in water within 5 minutes.
KR1020110146048A 2011-12-29 2011-12-29 Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose KR101806262B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020110146048A KR101806262B1 (en) 2011-12-29 2011-12-29 Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110146048A KR101806262B1 (en) 2011-12-29 2011-12-29 Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose

Publications (2)

Publication Number Publication Date
KR20130077373A true KR20130077373A (en) 2013-07-09
KR101806262B1 KR101806262B1 (en) 2017-12-08

Family

ID=48990637

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110146048A KR101806262B1 (en) 2011-12-29 2011-12-29 Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose

Country Status (1)

Country Link
KR (1) KR101806262B1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101431232B1 (en) * 2012-06-15 2014-08-18 (주)한국파비스제약 Pharmaceutical combination preparation for treatment of diabetes mellitus
KR20160065367A (en) 2014-11-28 2016-06-09 주식회사 휴온스글로벌 Pharmaceutical formulation containing alginic acid or its pharmaceutically acceptable salts and alkali salts of carboxymethyl cellulose and preparation methods thereof
WO2019006277A1 (en) * 2017-06-29 2019-01-03 Basf Se Water stable granules and tablets
CN112806496A (en) * 2021-01-19 2021-05-18 吴华东 Preparation method of high-stability poultry vitamin preparation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101431232B1 (en) * 2012-06-15 2014-08-18 (주)한국파비스제약 Pharmaceutical combination preparation for treatment of diabetes mellitus
KR20160065367A (en) 2014-11-28 2016-06-09 주식회사 휴온스글로벌 Pharmaceutical formulation containing alginic acid or its pharmaceutically acceptable salts and alkali salts of carboxymethyl cellulose and preparation methods thereof
WO2019006277A1 (en) * 2017-06-29 2019-01-03 Basf Se Water stable granules and tablets
CN112806496A (en) * 2021-01-19 2021-05-18 吴华东 Preparation method of high-stability poultry vitamin preparation

Also Published As

Publication number Publication date
KR101806262B1 (en) 2017-12-08

Similar Documents

Publication Publication Date Title
US20210023078A1 (en) Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
KR20130077373A (en) Water stable film-coating tablet comprising alginic acid and sodium carboxymethylcellulose
US20140037725A1 (en) Bilayer pharmaceutical compositions of naproxen
JP2007197410A (en) Film-coated tablet
US10668069B2 (en) Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof
CN1993131B (en) Film-coated tablet
CN100423722C (en) Oral enteric micro-pills contg. pantoprazole or its salts and preparing process thereof
JP5047572B2 (en) Method for producing solid pharmaceutical preparation with odor prevention, and solid pharmaceutical preparation obtained thereby
US9561242B2 (en) Doxycycline composition
KR101524264B1 (en) Oral pharmaceutical composition containing valsartan
JP2021091624A (en) Sorafenib tosylate preparation
JP6684915B2 (en) Carvedilol immediate release formulation having improved moisture absorption}
JP2018184382A (en) Ezetimibe-containing tablet and method for producing the same
CN104095850B (en) A kind of stable Pitavastatin calcium medicine compound and preparation method thereof
JP2018058786A (en) Pharmaceutical composition, production method for pharmaceutical composition, and method of improving stability of amorphous body
US20160338949A1 (en) Stabilized gastroretentive tablets of pregabalin
JP2022031068A (en) Ramelteon-containing coated tablet
JP6339800B2 (en) Miglitol-containing coating formulation
JP2021116284A (en) Ezetimibe and atorvastatin-containing pharmaceutical composition
JP2024007795A (en) Ezetimibe/rosuvastatin-compounded tablet
KR20080000121A (en) Methods and compositions of stabilizing sod. rabeprazole
NZ622639B2 (en) TABLET COMPRISING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
OA17035A (en) Tablet Comprising 7-[4-(4-benzo[b]thiophen4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant